Hu­mani­gen warns of bank­rupt­cy af­ter fail­ing to bounce back from Covid-19 EUA re­jec­tion 

Hu­mani­gen warned in an SEC fil­ing on Tues­day morn­ing that it like­ly won’t sur­vive af­ter its Covid-19 an­ti­body was re­ject­ed by the FDA in fall 2021.

The Short Hills, NJ-based biotech said it is “ex­plor­ing all re­struc­tur­ing op­tions, which may in­clude com­menc­ing a bank­rupt­cy or oth­er in­sol­ven­cy pro­ceed­ing some­time in the third quar­ter of 2023.”

Three Hu­mani­gen board mem­bers al­so re­signed last week, and with that, trad­ing in the com­pa­ny’s shares $HGEN will be sus­pend­ed from to­mor­row.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER